COVID-19: Case fatality and ACE2 inhibitors treatment concerns in patients with comorbidities

The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host rece...

Descripción completa

Detalles Bibliográficos
Autores principales: Aghili, Rokhsareh, Honardoost, Maryam, Khamseh, Mohammad E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Iran University of Medical Sciences 2020
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787016/
https://www.ncbi.nlm.nih.gov/pubmed/33437743
http://dx.doi.org/10.34171/mjiri.34.147
Descripción
Sumario:The Corona Virus Disease 2019 (COVID-19) outbreak is becoming pandemic with the highest mortality in patients with associated comorbidities. These RNA viruses containing 4 structural proteins usually use spike protein to enter the host cell. Angiotensin-converting enzyme 2 (ACE2) acts as a host receptor for the virus. Therefore, medications acting on renin-angiotensin-aldosterone system can lead to serious complications, especially in patients with diabetes and hypertension. To avoid this, other potential treatment modalities should be used in COVID-19 patients with associated comorbidities.

Ejemplares similares